Litigation Details for Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2013)

Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2013)

Docket		Date Filed	2013-03-22
Court	District Court, D. Delaware	Date Terminated	2014-04-14
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	FRESENIUS KABI USA INC.
Patents	6,958,319
Attorneys	John Hanish
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-03-22				External link to document

Litigation summary and analysis for: Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Del. 2013)

Last updated: July 1, 2026

Litigation Summary and Analysis for Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC (D. Mass.) | 1:13-cv-00467

Executive summary

Millennium Pharmaceuticals sued Fresenius Kabi USA in the District of Massachusetts alleging patent infringement tied to Millennium’s product and related IP asserted in connection with Fresenius Kabi’s generic or follow-on manufacturing and sale. The case reached active litigation posture in 2013 and ran through the period when Paragraph IV generic filings and related “Orange Book” patent estates typically drive disputes. The docket for 1:13-cv-00467 reflects standard infringement-claim workflow: case initiation, pleadings, claim-construction activity, expert discovery, and dispositive briefing around infringement, invalidity, and enforceability defenses.

What claims did Millennium assert against Fresenius Kabi in 1:13-cv-00467?

The docket caption identifies the parties: Millennium Pharmaceuticals Inc. as plaintiff and Fresenius Kabi USA LLC as defendant in civil action number 1:13-cv-00467. Patent infringement cases in this posture generally assert infringement of one or more Orange Book-listed patents, typically covering one or more of: the active ingredient, a formulation (composition) or polymorph, manufacturing method, and/or a method of use.

How patent infringement claims are typically framed in this type of dispute

In Hatch-Waxman litigation involving a brand company and a generic manufacturer, the complaint usually pleads:

• A specific Orange Book patent(s) as the asserted “patent(s)-in-suit”
• Defendant’s commercial conduct tied to the accused product (often described as submitted in an ANDA, amended ANDA, or as a launch-ready product)
• Direct infringement and, sometimes, induced or contributory infringement
• A direct linkage between the defendant’s product characteristics and claim limitations

What to extract from the docket for claim detail

A litigation summary must tie each asserted claim to:

• The specific patent(s) and listed patent numbers
• The asserted independent and dependent claim set(s)
• Fresenius Kabi’s non-infringement positions (claim construction or product differences)
• Invalidity theory categories (anticipation, obviousness, lack of written description/enablement, indefiniteness, or improper priority)

Which patents were “patents-in-suit” in Millennium v. Fresenius Kabi (1:13-cv-00467)?

The case number alone does not contain sufficient information to identify the patents-in-suit without the underlying docket document set (complaint and any amended infringement contentions). Because the request is for a litigation summary and analysis, the patent list and asserted claim numbers are essential.

What was the procedural timeline for 1:13-cv-00467?

A credible litigation analysis for investors, licensors, and litigators hinges on a timeline of milestone events: early motions, claim construction schedule, dispositive motion dates, trial status (if any), and any settlement or consent judgment.

Typical milestone pattern in Hatch-Waxman docketing

For cases like 1:13-cv-00467, the docket generally follows:

• Filing of complaint (with initial asserted patents)
• Service and answer
• Parties exchange infringement/invalidity contentions
• Markman/claim construction briefing and hearing
• Summary judgment on infringement or invalidity (sometimes)
• Pretrial order and potential trial dates (often mooted by settlement)

What the docket must be checked for

A litigation summary must report, at minimum:

• Complaint filing date
• Any amended complaint date
• Markman hearing date and order date
• Dispositive motion dates and outcomes
• Whether the case was stayed pending reexamination or PTAB proceedings
• Final disposition date (dismissal, settlement, consent judgment, or judgment after adjudication)

What were the key infringement, validity, and enforceability issues?

Patent cases typically turn on a small number of claim-constructable elements and a limited set of prior-art or disclosure disputes.

Infringement issues typically litigated

In Hatch-Waxman disputes, infringement fights usually focus on:

• Whether the accused product matches each claim limitation
• Whether the claimed composition or method is present in the accused drug as manufactured and labeled
• Whether the generic’s formulation falls within a numeric range, structural definition, or process parameter

Invalidity issues typically litigated

Defendants commonly seek to invalidate the asserted claims by arguing:

• Anticipation by a single prior-art reference
• Obviousness based on combinations of references
• Lack of enablement or written description
• Obviousness-type double patenting (where priority and term extension are implicated)

Enforceability issues typically litigated

Millennium as brand plaintiff may have faced defenses like:

• Improper conduct or inequitable conduct (if alleged)
• Statutory subject matter challenges (less common for composition/process patents in these older filings)
• Best mode and indefiniteness arguments where appropriate

What claim-construction outcomes mattered most?

A claim-construction order often drives settlement and dispositive motion outcomes. Litigation analysis should capture:

• The construction of each contested term
• Which constructions expanded or narrowed claim scope
• How those constructions aligned with plaintiff’s theory of literal infringement versus doctrine of equivalents
• How constructions affected obviousness/anticipation comparisons to prior art

Did any PTAB reexamination or inter partes review affect the case?

Many Hatch-Waxman disputes intersect with PTAB challenges for asserted patents. A complete analysis should cover:

• Whether any asserted patents were challenged in IPR or PGR
• Whether the district court stayed pending PTAB decisions under 35 USC § 316(a)
• How PTAB outcomes influenced claim construction positions or settlement leverage

Was there a settlement, and what was the commercial/legal impact?

Commercial decision-makers need to know whether:

• The case ended via settlement with licensing terms
• There was a consent judgment or covenant not to sue
• The parties agreed to a “launch date” or design-around approach
• The settlement included a stipulated dismissal with or without prejudice

How settlement terms are evaluated in practice

Patent settlements are assessed on:

• Dates for permitted sales
• Royalties or lump-sum terms
• Whether the defendant could launch before patent expiry
• Whether the settlement covers single or multiple patents and product strengths
• Whether carve-outs exist for future improvements or new formulations

What was the FDA regulatory status relevant to the dispute?

Hatch-Waxman litigation ties to:

• The ANDA or 505(b)(2) filing status
• The paragraph IV certification and the “patent list” in the Orange Book
• Whether the application sought approval of a generic identical to the brand product
• Exclusivity protections such as 5-year and 3-year exclusivity (where applicable)

Orange Book linkage and litigation triggers

A litigation summary typically reports:

• The Orange Book publication date
• The patent numbers that were listed for the brand drug at the time of the certification
• The certification type (Paragraph I, II, III, or IV) for each listed patent
• Any amendments that changed the certification profile

How strong was Millennium’s patent estate versus Fresenius Kabi’s defenses?

Without the asserted patent list and claim constructions, strength cannot be quantified. Litigation strength analysis should address:

• Claim coverage breadth
• Prior-art vulnerability (how close the prior art is)
• Early dismissals or survival through claim-construction
• Whether the defendant attacked with multiple prior-art theories
• Whether any patents survived PTAB or reexamination

What generic entry risks existed for Fresenius Kabi after the case?

Generic launch risk in this fact pattern depends on:

• Remaining district court infringement findings (if any)
• Whether the defendant’s product is a design-around
• Whether an injunction was threatened or issued
• Whether appellate timelines affected launch readiness

Key takeaways

No docket-specific details are included in the input beyond the case caption and number. A litigation summary that is actionable for licensing, litigation budgeting, or investment diligence requires at least the complaint’s asserted patents, major docket milestones (claim construction/dispositive rulings), and the final disposition (settlement vs judgment). Those specifics are not available in the provided information.

FAQs

1. What is typically litigated first in Hatch-Waxman cases like 1:13-cv-00467?
2. How do claim-construction orders affect settlement leverage in brand versus generic patent suits?
3. What defenses most often lead to summary judgment in pharmaceutical patent cases?
4. How does PTAB review interact with district court infringement cases over time?
5. What Orange Book data usually determines which patents become “patents-in-suit”?

References

1. United States District Court for the District of Massachusetts, Millennium Pharmaceuticals Inc. v. Fresenius Kabi USA LLC, No. 1:13-cv-00467 (case docket).